Kazia Therapeutics Limited (NASDAQ:KZIA – Get Free Report)’s share price shot up 4.4% during trading on Wednesday . The stock traded as high as $6.96 and last traded at $6.40. 197,623 shares changed hands during trading, a decline of 56% from the average session volume of 445,152 shares. The stock had previously closed at $6.13.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Kazia Therapeutics in a research note on Friday, July 12th.
Read Our Latest Stock Analysis on KZIA
Kazia Therapeutics Price Performance
About Kazia Therapeutics
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
Featured Stories
- Five stocks we like better than Kazia Therapeutics
- When to Sell a Stock for Profit or Loss
- What a Trump Win Looks Like for the Market Now and Into 2025
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What Are Growth Stocks and Investing in Them
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
